|
|
|
| Predictive Value of Systemic Immune-Inflammation Index Combined with BMI for Early Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents |
| Tan Kaiqin1, Huang Chaodi2,* |
1. Panyu Campus Pediatrics,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,China,510000;
2. Dermatology Department,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,China,510000 |
|
|
|
|
Abstract Objective To evaluate the predictive value of the systemic immune-inflammation index(SII)combined with body mass index(BMI)for early metabolic dysfunction-associated steatotic liver disease(MASLD)in adolescents. Methods A cross-sectional study was conducted using data from 1,227 adolescents in the 2017~2020 National Health and Nutrition Examination Survey(NHANES).Early MASLD was defined by a controlled attenuation parameter(CAP)248 dB/m.Multivariable logistic regression was used to identify risk factors for MASLD and construct a combined predictive model.The predictive performance was evaluated using the receiver operating characteristic(ROC)curve. Results Among the 1,227 participants,the prevalence of early MASLD was 26.8%(329/1,227).Multivariable regression analysis showed that BMI category was an independent risk factor for early MASLD,with obese adolescents having a 4.730-fold higher risk compared to those with normal weight(95% CI: 3.947-5.668,P<0.001).ROC analysis revealed that the area under the curve(AUC)for SII and BMI category alone was 0.610 and 0.819,respectively.The combined predictive model significantly improved the AUC to 0.827(95% CI: 0.800-0.855,P<0.001).Furthermore,a synergistic effect between SII and obesity was observed,with high SII status increasing the prevalence of MASLD by 14.0% in the overweight/obese group. Conclusion The combination of SII and BMI provides a robust and non-invasive tool for predicting early MASLD in adolescents.Given its cost-effectiveness and accessibility,this model can assist clinicians in identifying high-risk individuals for early intervention.
|
|
Received: 01 April 2026
|
|
|
|
|
|
[1] Rinella ME.A multi-society Delphi consensus statement on new nomenclature for steatotic liver disease.Hepatology.2023;78(6):1966-1986.
[2] Schwimmer JB Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity.The Journal of Pediatrics.2019;207:64-70.e2.
[3] Eddowes PJ Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology.2019;156(6):1717-1730.
[4] Rinella ME,Neuschwander-Tetri BA,Siddiqui MS,et al.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology.2023;77(5):1797-1835.
[5] Hu B,Yang XR,Xu Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.Clin Cancer Res.2014;20(23):6212-6222.
[6] Tilg H,Moschen AR.Evolution of inflammation in nona-lcoholic fatty liver disease: the multiple hit hypothesis.Hepatology.2010;52(5):1836-1846.
[7] Karlas T,Petroff D,Sasso M,et al.Individual patient data meta-analysis of controlled attenuation parameter(CAP)for assessing liver steatosis.J Hepatol.2017;66(5):1022-1030.
[8] Atsawarungruangkit A,Elfanagely Y,Pan J,et al.Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United States' adolescent population.World[J] Hepatol.2021;13(7):788-802.
[9] 肖益,潘宇帆,戴雨,等.中国超重/肥胖儿童青少年非酒精性脂肪性肝病患病率及危险因素的Meta分析[J].Chinese Journal of Contemporary Pediatrics,2025,27(4).
[10] 邱林杰,任海燕,任燕,等.全身免疫炎症指数和不同肥胖表型对体检人群心脏代谢性共病的联合影响[J].中国医药,2025,20(11):1613-1617.
[11] 段亚梅. 肥胖儿童炎性标志物与非酒精性脂肪肝病的关联研究[D].中南大学,2023. |
|
|
|
2026, Vol. 46 
